PharmaEssentia Hits NT$1,600 Record High on Twin Catalysts; Analysts See NT$1,900 Target — BigGo Finance

New drug developer PharmaEssentia (6446.TW) delivered a powerful performance on Tuesday, opening higher at NT$1,520 before climbing steadily to an intraday peak of NT$1,600 — a gain of more than 7% and a fresh all-time high. As of midday, the stock was trading at NT$1,590, holding gains above 6%, with trading volume exceeding 2,800 lots and ranking 31st among Taiwan’s high-priced stocks.

The rally was fueled by two major potential catalysts. Market sources indicate that PharmaEssentia’s market capitalization has surpassed NT$630 billion (approximately $19.8 billion), placing it among the top 40 listed companies in Taiwan and positioning it for inclusion in the Yuanta Taiwan Top 50 ETF (0050) during the September constituent review, prompting institutional investors to position ahead of the announcement. From a fund-flow perspective, foreign investors sold a net 333 lots on Monday, while domestic investment trusts bought a net 30 lots, suggesting institutional players are already preparing for the index adjustment.

The other key catalyst stems from consecutive breakthroughs for the company’s core drug Ropeg (brand name Besremi) in the Essential Thrombocythemia (ET) indication. PharmaEssentia recently announced that Ropeg has received approval from Japan’s Ministry of Health, Labour and Welfare for ET treatment — marking the first approval covering all ET patients — adding another major overseas market to its regulatory wins following Taiwan and Macau.

Even more closely watched is progress in the U.S. market. The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target date of August 30 for Ropeg’s ET indication, leaving only days before the decision deadline. Industry observers note that since the FDA approved Anagrelide as a second-line therapy in 1997, the ET field has seen no new drug approvals for nearly three decades, underscoring a clear and urgent unmet medical need. If Ropeg secures approval, it would fill this long-standing clinical gap.

Analysts at institutional research firms believe that as PharmaEssentia accumulates ET approvals across multiple countries, with Japan and the U.S. entering full sales years in 2026, the ET indication could become another growth driver alongside Polycythemia Vera (PV). The company is actively preparing for U.S. commercialization post-approval, with existing active pharmaceutical ingredient capacity at its Taichung CGMP facility supplemented by the upcoming completion of its Zhubei plant, further enhancing global supply capabilities to meet demand from the dual-indication ramp-up.

Reviewing PharmaEssentia’s second-quarter performance, quarterly revenue reached NT$6.86 billion (approximately $215.4 million), up 90.3% year-over-year. Benefiting from retroactive rebates tied to improved U.S. customer service and discount terms, as well as May product price adjustments, gross margin improved significantly to 94.2%, up 6.3 percentage points from the prior quarter. Operating profit reached NT$3.15 billion (approximately $99.1 million) with an operating margin of 46.0%, while net income came in at NT$2.53 billion (approximately $79.5 million), translating to earnings per share of NT$6.13 for the quarter. Cumulative first-half EPS reached NT$11.92.

Looking ahead, analysts project PharmaEssentia’s full-year 2026 revenue to reach NT$30.24 billion (approximately $950.2 million), up 93.4% year-over-year, with EPS of NT$26.68. In 2027, driven by multiple major markets entering full sales years and improved reimbursement coverage, revenue is expected to grow to NT$47.4 billion (approximately $1.5 billion), up 56.7%, with projected EPS of NT$42.27.

Based on the steady expansion of the PV franchise, ET approvals in major markets entering the harvest phase, dual-indication revenue stacking, and complete production capacity readiness, the institutional research firm applied a 45x price-to-earnings multiple — at the upper-middle range of the historical band — to raise PharmaEssentia’s price target to NT$1,900, maintaining a “Buy” rating.

However, analysts also cautioned that with Tuesday’s substantial gains, short-term investors chasing the rally should be mindful of profit-taking pressure, and there remains uncertainty as to whether the U.S. ET approval will be secured on schedule by August 30. Investors are advised to closely monitor subsequent official company announcements.